Anti-Influenza Drug Avigan® Tablet Meets Primary Endpoint in Phase III Clinical Trial in Japan for COVID-19 Patients
TOKYO — September 23, 2020 FUJIFILM Toyama Chemical Co., Ltd. (President: Junji Okada; hereina...
Japan secures 120 mn doses of potential corona-vaccine: pharma group
Japan has signed a deal to secure 120 million dose...
New wave of infections threatens to collapse Japan hospitals
Hospitals in Japan are increasingly turning away s...
Japan city seeks raincoats as emergency protection for virus staff
Japan’s third-biggest city has appealed for ...